Lymphogranuloma venereum pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 3: Line 3:
{{CMG}}
{{CMG}}


==Overview==
==Pathophysiology==
==Pathophysiology==
===Transmission===
===Transmission===
LGV is passed from person to person through direct contact with lesions, [[ulcer]]s or other area where the bacteria is located. Transmission of the organism occurs during sexual penetration (vaginal, oral, or anal) and may also occur via skin to skin contact. The likelihood of LGV infection following an exposure is unknown, but it is considered less infectious than some other STDs. A person who has had sexual contact with a LGV-infected partner within 60 days of symptom onset should be examined, tested for [[urethra]]l or [[cervical]] [[chlamydia]]l infection, and treated with [[doxycycline]], twice daily for 7 days.
LGV is passed from person to person through direct contact with lesions, [[ulcer]]s or other area where the bacteria is located. Transmission of the organism occurs during sexual penetration (vaginal, oral, or anal) and may also occur via skin to skin contact. The likelihood of LGV infection following an exposure is unknown, but it is considered less infectious than some other STDs. A person who has had sexual contact with a LGV-infected partner within 60 days of symptom onset should be examined, tested for [[urethra]]l or [[cervical]] [[chlamydia]]l infection, and treated with [[doxycycline]], twice daily for 7 days.


==Sources==
*http://www.cdc.gov/
==References==
==References==
{{reflist|2}}
{{reflist|2}}


[[Category:Sexually transmitted diseases]]
[[Category:Sexually transmitted diseases]]
[[Category:Disease]]
[[Category:Disease]]
[[Category:Gynecology]]
[[Category:Gynecology]]

Revision as of 14:22, 11 December 2012

Lymphogranuloma venereum Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Classification

Differentiating Lymphogranuloma venereum from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Lymphogranuloma venereum pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Lymphogranuloma venereum pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Lymphogranuloma venereum pathophysiology

CDC on Lymphogranuloma venereum pathophysiology

Lymphogranuloma venereum pathophysiology in the news

Blogs on Lymphogranuloma venereum pathophysiology

Directions to Hospitals Treating Lymphogranuloma venereum

Risk calculators and risk factors for Lymphogranuloma venereum pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Pathophysiology

Transmission

LGV is passed from person to person through direct contact with lesions, ulcers or other area where the bacteria is located. Transmission of the organism occurs during sexual penetration (vaginal, oral, or anal) and may also occur via skin to skin contact. The likelihood of LGV infection following an exposure is unknown, but it is considered less infectious than some other STDs. A person who has had sexual contact with a LGV-infected partner within 60 days of symptom onset should be examined, tested for urethral or cervical chlamydial infection, and treated with doxycycline, twice daily for 7 days.

References


Template:WikiDoc Sources